List of Excipients in Branded Drug RIVFLOZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novo Nordisk	RIVFLOZA	nedosiran	0169-5306	WATER	2035-10-29

Rivfloza Excipient Strategy and Commercial Opportunities for Nedosiran

Last updated: August 9, 2026

Rivfloza (nedosiran) is a monthly subcutaneous small-interfering RNA therapy approved by the U.S. Food and Drug Administration for adults and children aged 9 years and older with primary hyperoxaluria type 1, or PH1, and relatively preserved kidney function. Its commercial excipient strategy is deliberately conventional: an aqueous, ready-to-use solution containing phosphate buffer, sodium chloride, polysorbate 80, and water for injection. The largest opportunities are not likely to come from replacing the core excipients. They are more likely to come from improving dose flexibility, device presentation, storage robustness, pediatric usability, and combination products.

Rivfloza targets hepatic lactate dehydrogenase, or LDH, through RNA interference. It is administered once monthly by subcutaneous injection. The product is supplied in single-dose prefilled syringes at a concentration of 160 mg/mL, with weight-based dose options for pediatric and lower-body-weight patients.[1]

What excipients are used in Rivfloza?

Rivfloza uses a four-component inactive-ingredient system designed for a liquid oligonucleotide injection.

Component	Function in the formulation	Commercial relevance
Nedosiran sodium	Active RNAi drug substance	Determines concentration, viscosity, aggregation, and dose volume
Phosphate buffer	pH control	Supports chemical stability and tolerability
Sodium chloride	Tonicity adjustment	Helps produce an acceptable subcutaneous formulation
Polysorbate 80	Surfactant	Reduces interfacial adsorption and aggregation
Water for injection	Vehicle	Provides the aqueous delivery medium

The U.S. prescribing information identifies phosphate buffer, sodium chloride, polysorbate 80, and water for injection as inactive ingredients.[1] The formulation is supplied as a sterile solution rather than a lyophilized powder, reducing reconstitution steps and supporting administration through a prefilled syringe.

Why does Rivfloza use polysorbate 80?

Polysorbate 80 is commonly used in biologic and oligonucleotide products to limit adsorption to container surfaces and reduce agitation-induced aggregation. In a prefilled syringe, the surfactant can reduce losses at the glass, elastomer, and liquid-air interfaces.

Its use creates several development obligations. Polysorbate 80 can undergo hydrolysis and oxidation, generating degradation products that may affect product quality. The sponsor must control peroxide levels, fatty-acid composition, visible and subvisible particles, and compatibility with the syringe system. These attributes are important for a monthly injectable administered chronically to pediatric and adult patients.

Why are phosphate and sodium chloride commercially important?

Phosphate provides pH control, while sodium chloride helps establish near-physiologic tonicity. Both are low-cost, widely available materials with established parenteral-use histories. That lowers manufacturing and regulatory complexity compared with novel buffering or tonicity systems.

The tradeoff is that phosphate systems can interact with metal ions and container components under some conditions. Buffer concentration, pH, ionic strength, and freeze-thaw exposure must be optimized against RNA integrity, particle formation, and syringe compatibility.

What formulation is protected by Rivfloza’s excipient strategy?

The public label establishes the commercial formulation, but excipient composition alone may provide limited freedom-to-operate protection. The more defensible intellectual-property position generally comes from the combined product architecture:

• Nedosiran sequence and chemical modifications
• RNAi mechanism and LDH targeting
• Conjugation or delivery chemistry
• Dose and dosing interval
• Treatment of PH1
• Concentration and administration regimen
• Prefilled-syringe presentation
• Stability and manufacturing controls

A generic copy would not necessarily need to reproduce every excipient or the same device. It would need to demonstrate pharmaceutical equivalence or an appropriate alternative under the applicable FDA pathway. For a complex oligonucleotide injection, differences in particle profile, aggregation, potency, impurity levels, delivery chemistry, or pharmacodynamic response could create substantial regulatory work.

Which excipients are most likely to support follow-on patents?

Potential formulation claim areas include:

1. Low-concentration surfactant systems. Claims could focus on polysorbate concentration ranges that limit adsorption without increasing oxidation or injection-site reactions.

2. Alternative surfactants. Poloxamers, polysorbate 20, or newer nonionic surfactants could be evaluated, although each would require compatibility and safety data.

3. Buffer systems. Histidine, citrate, acetate, or other buffers could create differentiated formulations if they improve stability, reduce particles, or support a different storage condition.

4. High-concentration formulations. A higher-strength formulation could reduce injection volume or enable a smaller autoinjector, subject to viscosity and tolerability constraints.

5. Preservative-free multidose systems. This would be technically and commercially relevant but would require a container-closure system that maintains sterility throughout repeated use.

6. Lyophilized or spray-dried presentations. A solid-state formulation could improve temperature stability, but it would add reconstitution steps and likely reduce the convenience advantage of the current prefilled syringe.

The strongest commercial formulation claims would combine composition with a measurable outcome, such as improved chemical stability, reduced aggregation, lower injection volume, extended refrigerated shelf life, or improved delivery-device performance.

What commercial opportunities exist for Rivfloza excipients?

The near-term opportunity is incremental product improvement rather than a wholesale excipient replacement.

1. Higher-concentration and lower-volume products

The approved 160 mg/mL presentation supports weight-based dosing. A higher-concentration formulation could reduce injection volume for the 160 mg dose and improve usability for chronic home administration. The commercial value would be highest if the reformulation enables:

• A shorter injection time
• A smaller prefilled syringe
• Autoinjector compatibility
• Lower injection-site burden
• Better pediatric handling

Higher concentration increases the risk of viscosity, aggregation, syringe glide-force problems, and injection discomfort. A successful formulation would need to preserve potency and particle control at higher drug loading.

2. Device-compatible excipient systems

The most attractive excipient opportunity may be a formulation-device package. Syringe materials, lubricant levels, needle geometry, and surfactant concentration interact directly. A lower-silicone or silicone-free syringe could reduce particulate risk or improve stability, but it may require different lubrication and container-closure controls.

A company supplying specialty surfactants, low-peroxide polysorbate 80, coated syringes, or low-extractables elastomers could target Rivfloza and similar RNA therapeutics through platform agreements rather than a product-specific license.

3. Improved temperature stability

Rivfloza is refrigerated under the U.S. label. A formulation that tolerates controlled room-temperature excursions would have material value for home delivery, specialty-pharmacy distribution, and international markets. The likely development path would involve:

• Lower-peroxide surfactant grades
• Optimized pH and ionic strength
• Chelation or metal-control strategies
• Improved container-closure materials
• Real-time and accelerated stability data

Temperature-stable RNAi products could reduce cold-chain expense and product loss. The commercial case depends on whether the stability gain supports a meaningful label claim rather than only internal shipping flexibility.

4. Pediatric dose presentations

PH1 is a pediatric disease, and Rivfloza includes weight-based dosing. Pediatric usability creates opportunities for:

• Smaller-volume prefilled syringes
• Dose-specific presentations
• Needle shielding
• Autoinjectors for older children
• Simplified caregiver administration
• More visible dose confirmation

Separate presentations may increase packaging and inventory costs. A variable-dose device could reduce stock-keeping units but would introduce human-factors and dosing-error considerations.

5. Combination and co-packaging opportunities

PH1 patients may receive multiple therapies, including pyridoxine in appropriate patients and supportive measures intended to reduce oxalate burden. A co-packaged regimen could improve adherence, although a fixed combination would face clinical, regulatory, and commercial barriers.

The more practical opportunity is a coordinated specialty-pharmacy package that includes administration supplies, patient education, renal monitoring support, and cold-chain management. Such services may generate commercial value without changing the drug formulation.

How does Rivfloza compare with Oxlumo on formulation and commercial positioning?

Oxlumo (lumasiran) is the closest commercial comparator. Both products are RNAi therapies for PH1 and are administered subcutaneously. They differ in target, dosing schedule, delivery chemistry, age eligibility, and commercial positioning.

Attribute	Rivfloza	Oxlumo
Active ingredient	Nedosiran	Lumasiran
Sponsor	Novo Nordisk	Alnylam Pharmaceuticals
Molecular target	Hepatic LDH	Hepatic glycolate oxidase
Disease	PH1	PH1
Administration	Subcutaneous	Subcutaneous
Dosing pattern	Monthly, weight-based	Loading and maintenance schedule, including monthly or quarterly maintenance depending on patient weight
Formulation type	Ready-to-use aqueous injection	Ready-to-use aqueous injection
Primary commercial differentiation	Monthly dosing and LDH pathway inhibition	Earlier market entry and established PH1 RNAi franchise

Oxlumo received FDA approval in November 2020, while Rivfloza received FDA approval in October 2023.[2,3] The competing products address the same rare disease population, making convenience, renal-function criteria, access, physician familiarity, and long-term safety central commercial variables.

For excipient suppliers, the two products demonstrate that PH1 is a small but technically sophisticated market. A platform excipient or device solution that improves storage, injection volume, or pediatric administration could have value across RNAi products, but a single-product opportunity may be limited by the small addressable population.

What is the FDA regulatory status of Rivfloza?

Rivfloza was approved under NDA 215500 for PH1 in patients aged 9 years and older with relatively preserved kidney function.[1] The product is an oligonucleotide therapeutic rather than a conventional small-molecule tablet. It is not a biologic interchangeable product, so the biosimilar framework does not govern follow-on competition.

A reformulated Rivfloza presentation could require a supplemental NDA if the sponsor changes the composition, strength, container, delivery device, or storage conditions. The regulatory burden would depend on the change:

• Minor excipient adjustment: formulation comparability, stability, and safety data
• New concentration: dose-volume, pharmacokinetic, pharmacodynamic, and injection-site evaluation
• New device: combination-product and human-factors requirements
• New route or schedule: clinical development likely required
• New storage condition: extended stability and packaging data

The FDA’s pharmaceutical-quality expectations for oligonucleotide injections include control of identity, purity, sequence-related impurities, degradation products, potency, sterility, endotoxins, visible and subvisible particles, and container-closure integrity.[4]

When does Rivfloza lose exclusivity?

Rivfloza’s commercial exclusivity is likely to depend more on composition-of-matter, RNAi platform, delivery, and method-of-use patents than on excipient patents alone. The product also benefits from regulatory exclusivity associated with its orphan-drug designation, subject to the scope of the approved indication.

Orphan-drug exclusivity generally provides seven years of U.S. market exclusivity from approval for the same indication under the Orphan Drug Act.[5] Patent expiration dates must be verified against current USPTO records, FDA Orange Book listings, patent-term adjustments, patent-term extensions, and any litigation or settlement agreements.

For a complex RNAi product, a first generic challenge may face higher technical barriers than a conventional oral drug because a copy must address:

• Sequence and chemical-structure differences
• Delivery and tissue-distribution performance
• Potency and impurity comparability
• Sterile injectable manufacturing
• Device presentation
• Clinical and pharmacodynamic bridging

Is Rivfloza vulnerable to Paragraph IV challenges?

A Paragraph IV challenge is legally possible if relevant patents are listed in the Orange Book and an applicant files an ANDA alleging invalidity, unenforceability, or noninfringement. The practical likelihood depends on whether Rivfloza’s key protections are Orange Book-listed drug patents, non-listed platform patents, orphan exclusivity, or a combination of these.

For RNAi products, important patents may cover delivery chemistry, target sequence, conjugation, manufacturing, or treatment methods. Not all such patents necessarily create the same ANDA litigation pathway. A competitor could also pursue a 505(b)(2) application or another regulatory route if it cannot qualify as a conventional generic.

How strong is the Rivfloza patent estate?

The estate is likely strongest where multiple patent layers overlap:

Patent layer	Strategic role	Risk to follow-on entrants
Nedosiran composition and sequence	Protects the active molecule	High if claims are broad and enforceable
LDH-targeting RNAi methods	Protects therapeutic use	High for PH1-specific competitors
Delivery or conjugation chemistry	Protects liver uptake	High technical barrier
Formulation	Protects concentration, stability, or excipient ranges	Moderate unless clinically differentiated
Device and presentation	Protects administration convenience	Moderate
Manufacturing	Protects synthesis, purification, and impurity control	Moderate to high for complex RNA products

A strong estate would not rely exclusively on polysorbate 80, phosphate, or sodium chloride. Those materials are widely used and would be difficult to monopolize broadly. The business value lies in claiming specific combinations that solve measurable formulation problems.

Which companies are challenging Rivfloza?

No established biosimilar pathway applies to Rivfloza, and conventional generic competition is likely to be more difficult than for a small-molecule product. The most credible competitive threats are:

• Alnylam through Oxlumo
• Other RNAi developers targeting PH1 or oxalate metabolism
• Gene-editing or gene-therapy programs directed at hepatic oxalate production
• Small-molecule therapies that reduce oxalate generation or crystallization
• Follow-on oligonucleotide developers using alternative delivery systems

The principal competitive issue is not only price. It is whether a rival offers less frequent dosing, broader renal eligibility, easier administration, or stronger long-term outcomes.

What manufacturing and IP barriers affect commercial entry?

Nedosiran manufacturing requires control over oligonucleotide synthesis, purification, conjugation or delivery chemistry, sterile filtration, filling, and analytical characterization. These steps create barriers that are less common in conventional generics.

Key manufacturing risks include:

• Sequence-related impurities
• Truncated and deletion sequences
• Residual solvents and reagents
• Metal contamination
• Aggregation and particle generation
• Surfactant degradation
• Syringe compatibility
• Batch-to-batch potency variation

An excipient supplier can capture value by providing qualified low-peroxide surfactants, high-purity buffers, container-closure systems, or analytical methods. The strongest opportunity is a validated platform that reduces development time across several oligonucleotide products.

What is the revenue opportunity for Rivfloza excipient suppliers?

PH1 is a rare disease, so the total volume of Rivfloza excipients is likely modest compared with mass-market injectable drugs. The commercial value comes from high drug value per patient, chronic monthly dosing, and the premium placed on reliability.

Potential revenue pools include:

1. Primary excipients: phosphate, sodium chloride, polysorbate 80, and water for injection.
2. Specialty grades: low-peroxide and low-particulate polysorbate 80.
3. Container systems: prefilled syringes, elastomers, coatings, and needles.
4. Analytical services: particle, oxidation, aggregation, and extractables testing.
5. Lifecycle products: higher-concentration, room-temperature, pediatric, and autoinjector presentations.
6. Manufacturing partnerships: sterile fill-finish and oligonucleotide formulation services.

Commodity excipient supply is unlikely to create substantial strategic differentiation. Contractual qualification, dual sourcing, change-control support, and platform adoption across RNAi products are more defensible commercial positions.

Key Takeaways

• Rivfloza uses a conventional aqueous formulation based on phosphate buffer, sodium chloride, polysorbate 80, and water for injection.
• The best lifecycle opportunities involve higher concentration, lower injection volume, improved temperature stability, pediatric usability, and device integration.
• Excipient patents alone are unlikely to provide the principal exclusivity barrier. The stronger protections are expected to involve nedosiran, RNAi delivery, LDH targeting, treatment methods, and manufacturing.
• Rivfloza competes most directly with Alnylam’s Oxlumo, another PH1 RNAi therapy.
• Biosimilar substitution is not the relevant competitive framework. Follow-on risk is more likely to arise through complex generic, 505(b)(2), alternative RNAi, gene-therapy, or small-molecule pathways.
• For suppliers, specialty excipient grades and formulation-device platforms offer greater value than commodity phosphate or sodium chloride supply.

FAQs

Can Rivfloza be reformulated without changing its patent position?

A reformulation could receive separate composition or formulation protection, but it would not automatically extend all underlying patents or regulatory exclusivity. The value would depend on claim scope, patent-term timing, and whether the new presentation becomes commercially important.

Could a polysorbate-free Rivfloza formulation improve marketability?

It could reduce concerns about surfactant oxidation and certain extractables, but it could also increase adsorption, aggregation, and container-loss risks. A polysorbate-free formulation would need a replacement stabilizer or a substantially different container system.

Would a room-temperature Rivfloza product materially improve commercialization?

Yes. It could simplify specialty-pharmacy distribution and reduce cold-chain losses. The commercial benefit would be greatest in markets with limited refrigerated logistics and for home administration.

Could an autoinjector create new Rivfloza patent protection?

Potentially. Protection could cover the device, dose volume, injection sequence, needle configuration, or formulation-device combination. Device patents would complement, but not replace, patents covering nedosiran and its therapeutic use.

Is Oxlumo an excipient substitute for Rivfloza?

No. Oxlumo is a competing therapeutic product containing lumasiran, not an excipient or formulation substitute. Its commercial relevance is as an alternative PH1 RNAi treatment with a different molecular target and dosing schedule.

References

1. U.S. Food and Drug Administration. (2023). Rivfloza (nedosiran) injection: Prescribing information. Novo Nordisk.

2. U.S. Food and Drug Administration. (2023, October 12). FDA approves treatment for primary hyperoxaluria type 1. https://www.fda.gov

3. U.S. Food and Drug Administration. (2020, November 19). FDA approves first drug to treat rare metabolic disorder leading to kidney stones. https://www.fda.gov

4. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Oligonucleotide therapeutics chemistry, manufacturing, and controls. https://www.fda.gov

5. U.S. Food and Drug Administration. (2023). Orphan drug act: Relevant statutory provisions and exclusivity framework. https://www.fda.gov